Evidence map›Paper›PMID 39708197›Full record

ArticleClinical and experimental medicine2024

Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.

Aida Raventós, Elena G Arias-Salgado, Alba Pérez, María Teresa Alvarez-Román, Nora V Butta, Elena Monzon Manzano, Paula Acuña, Víctor Jiménez-Yuste, Montserrat Costa, María Isabel Bravo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aida Raventós *Discovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain. aida.raventos@grifols.com.ORCID http://orcid.org/0009-0002-1910-3651
Elena G Arias-Salgado *Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Alba PérezDiscovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain.
María Teresa Alvarez-RománHematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Nora V ButtaHematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Elena Monzon ManzanoHematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Paula AcuñaHematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Víctor Jiménez-YusteHematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Montserrat CostaDiscovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain.
María Isabel BravoDiscovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia A (HA) patients under emicizumab prophylaxis may require the concomitant use of procoagulant factors for breakthrough bleedings or immune tolerance induction (ITI). The aim of this study is to evaluate the ex vivo procoagulant effect of plasma-derived FVIII concentrates containing von Willebrand factor (pdFVIII/VWF) in samples from patients with severe HA without inhibitors on emicizumab prophylaxis. Samples from healthy controls (HC) and HA patients were drawn in sodium citrate plus corn trypsin inhibitor tubes and spiked with increasing concentrations of pdFVIII/VWF concentrates (10-400 IU/dL) (Fanhdi

Indexed as

Antibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIIIHemophilia Avon Willebrand FactorAdolescentAdultBlood CoagulationBlood Coagulation TestsHumansMaleMiddle AgedThrombelastographyYoung AdultAntibodies, BispecificAntibodies, Monoclonal, HumanizedemicizumabFactor VIIIvon Willebrand FactorEmicizumabHemophilia APlasma-derived FVIII concentrates containing von Willebrand factorProcoagulantRotational thromboelastometryThrombin generation assay

Identifiers

PMID39708197
PMCPMC11663164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.